Samuel D. Waksal
Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.
Samuel D. Waksal | |
|---|---|
| Born | Samuel David Waksal September 8, 1947 Paris, France |
| Nationality | American |
| Citizenship | United States |
| Education | PhD |
| Alma mater | Ohio State University |
| Occupation(s) | Scientist, biotechnology executive |
| Years active | 1979–present |
| Known for | Founder of ImClone Systems and Kadmon Pharmaceuticals |
| Board member of | Cadus Corporation, Antigenics Inc., Test University, Rockefeller University |
| Criminal charge(s) | fraud, conspiracy, perjury |
| Criminal penalty | 87 months imprisonment |
| Criminal status | released |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.